Showing results (311-320 of 3,787) with videos related to
Sort By:
Pageof 379
Oncoimmunology|May 19, 2023
B cells require licensing by dendritic cells to serve as primary antigen-presenting cells for plasmid DNAIchwaku Rastogi, Douglas G McNeelOncoimmunology|April 23, 2021
VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphomaHai-Xia He, Yan Gao, Jian-Chang Fu, et al.Oncoimmunology|May 14, 2023
A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8+ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinomaAzar Rezapour, Daniel Rydbeck, Fabian Byvald, et al.Oncoimmunology|April 15, 2021
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapiesJacquelot N, Tellier J, Nutt Sl, et al.Oncoimmunology|March 26, 2013
Neuropilin 1 guides regulatory T cells into VEGF-producing melanomaWiebke HansenOncoimmunology|March 26, 2013
How quantitative differences in dendritic cell maturation can direct TH1/TH2-cell polarizationManfred B LutzOncoimmunology|March 26, 2013
Engineering effective T-cell based antitumor immunityThomas Gruber, Reinhard Hinterleitner, Christa Pfeifhofer-Obermair, et al.Oncoimmunology|November 20, 2012
AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DCChang-Xuan You, Min Shi, Yong Liu, et al.Oncoimmunology|November 20, 2012
An ENU mutagenesis approach to dissect "self"-induced immune responses: Unraveling the genetic footprint of immunosurveillanceSiobhan Cashman, Kristin Lampe, Rachel Sheridan, et al.Oncoimmunology|November 20, 2012
Targeting the MHC Class II antigen presentation pathway in cancer immunotherapyJacques Thibodeau, Marie-Claude Bourgeois-Daigneault, Réjean LapointePageof 379